Blockers of ATP sensitive potassium current are of potential benefit in ischaemic heart disease.
Siegl
P
P
Merck Research Laboratories, Department of Pharmacology, West Point, PA 19486.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism; D026902:Potassium Channel Blockers; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers; D000254:Sodium-Potassium-Exchanging ATPase; D005905:Glyburide